- Home
- ADUS vs ELVN Comparison
ADUS vs ELVN Comparison
Compare ADUS & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADUS | ELVN |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.3B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ADUS | ELVN |
|---|---|---|
| Price | $94.48 | $43.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $135.40 | $43.40 |
| AVG Volume (30 Days) | 204.3K | ★ 1.7M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.40 | 3.17 |
| EPS | ★ 5.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $4.64 | N/A |
| P/E Ratio | $17.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $90.89 | $14.79 |
| 52 Week High | $124.44 | $46.31 |
Technical Indicators
Market Signals| Indicator | ADUS | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 70.86 |
| Support Level | N/A | $18.04 |
| Resistance Level | $118.51 | N/A |
| Average True Range (ATR) | 2.97 | 2.78 |
| MACD | 0.12 | 0.74 |
| Stochastic Oscillator | 37.51 | 86.13 |
Price Performance
Historical ComparisonAbout ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.